This is Cinclus Pharma
A Swedish pharma company developing effective treatment for GERD
Improving GERD treatment
Cinclus Pharma is a Swedish clinical-stage pharma company developing small molecules for the treatment of gastric acid-related diseases. Our lead candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD).
Taking the heritage from Astra to the next level
Cinclus Pharma was founded by pioneers in GERD treatment, both with extensive experience from Astra and AstraZeneca, where clinical Phase I and Phase II studies were performed on its product candidate linaprazan. Together with the team at Cinclus Pharma the founders are now taking the development of linaprazan glurate to the next level.
Improving the quality of life for people suffering from GERD
Today, PPI-based traditional GERD drugs do not offer efficient treatment for all patients. By developing linaprazan glurate into an advanced and effective medication Cinclus Pharma can make a difference in the everyday life of many individuals who are burdened by GERD. Every successful treatment of GERD also creates an indirect positive effect on the lives of the patients’ family, friends, and colleagues.
Join our team
Experience the positive culture at our fast-growing company Cinclus Pharma, where a highly skilled and motivated team is waiting for you. Check out our career page for more information about current vacancies.
Board of directors
The Board of Directors has international competence and extensive industry experience in life science.
Management team
Our management team has a proven track record in drug development within the field of acid inhibition.
